Epstein-Barr virus-attributable cancers among children and adolescents in Europe and North America: a meta-analysis

Clicks: 12
ID: 330742
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #229 of 374 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 374 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Epstein-Barr virus (EBV), a common childhood infection, is associated with Burkitt lymphoma, Hodgkin lymphoma, and nasopharyngeal cancer. We estimated the proportion and number of cancers attributable to EBV among individuals aged ≤19 years in Europe and North America in 2022. Methods Embase and MEDLINE were searched from inception to August 25th, 2025. Cancer incidence was derived from GLOBOCAN. We included studies where cancer tissue from ≥8 individuals aged ≤19 years residing in Europe or North America were tested for EBV. Pooled EBV prevalence and 95% confidence intervals (CIs) were estimated using random-effects models. To obtain EBV-attributable cases, pooled prevalence was multiplied by cancer incidence. Results After screening 17,388 titles/abstracts and 1,084 full-texts, 53 studies met the inclusion criteria for Burkitt lymphoma (9 studies, 433 cases), Hodgkin lymphoma (40 studies, 3197 cases), and nasopharyngeal cancer (4 studies, 62 cases). The pooled prevalence of EBV was 19.7% (CI: 10.2–34.7%, I2=69.5%) in Burkitt lymphoma, 33.4% (CI: 27.4–40.0%, I2=75.6%) in Hodgkin lymphoma, and 96.8% (CI: 88.0–99.2%, I2=0.0) in nasopharyngeal cancer. An estimated 1,166 (2.8%) of 41,366 cancers diagnosed in 2022, were attributable to EBV. These cases comprised 899 Hodgkin lymphomas, 140 Burkitt lymphomas, and 127 nasopharyngeal cancers. The burden was higher among males (3.2% vs 2.3% for females) and those aged 10–14 years (5.0% vs 1.7% for 0–9-year-olds and 3.1% for 15-19-year-olds). Conclusion In 2022, 2.8% of childhood cancers diagnosed in Europe and North America were attributable to EBV.
Reference Key
openalex_W7215087817 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Karena D. Volesky, Olga Tsyruk-Romano, Allan Hildesheim, Stephen D. Walter, Mariam El‐Zein, Christine M. Friedenreich, Darren R. Brenner, Eduardo Luis Franco
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag344
URL
https://doi.org/10.1093/jnci/djag344
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.